Program
Gemcitabine
Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.
Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 681 open or running | phase 3since Nov 6, 2000 | Nov 6, 2000 | May 2027phase 2 · NCT05999994 |
| Hoffmann-La Rocheits history only | 181 open or running | phase 4since Mar 19, 2008 | Apr 17, 2007 | Mar 22, 2027phase 1 · NCT06624085 |
| Pfizerits history only | 50 open or running | phase 3since Jan 21, 2000 | Jan 21, 2000 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 2since May 23, 2003 | May 23, 2003 | none ahead |
| Amgenits history only | 30 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 1since Apr 9, 2002 | Apr 9, 2002 | none ahead |
| NovoCureits history only | 20 open or running | phase 2since Oct 23, 2013 | Oct 23, 2013 | none ahead |
| Pierre Fabreits history only | 20 open or running | phase 2since Apr 16, 2012 | Apr 16, 2012 | none ahead |
| Sarah Cannon Research Instituteits history only | 20 open or running | phase 2since Apr 4, 2008 | Apr 4, 2008 | none ahead |
| Theriva Biologics SLits history only | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| BeBetter Medits history only | 10 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | none ahead |
| Betta Pharmaceuticalsits history only | 10 open or running | phase 4since Jul 16, 2014 | Jul 16, 2014 | none ahead |
| Coherus Oncologyits history only | 11 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Eisai | 10 open or running | phase 2since May 17, 2010 | May 17, 2010 | none ahead |
| Hope Cancer Instituteits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Jiangsu Healthy Life Innovation Medical Technologyits history only | 11 open or running | no phasesince Sep 20, 2024 | Sep 20, 2024 | none ahead |
| Meyer Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novaceaits history only | 10 open or running | phase 2since Sep 26, 2007 | Sep 26, 2007 | none ahead |
| Otsukaits history only | 10 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| Pharmacosmosits history only | 10 open or running | phase 2since Nov 18, 2016 | Nov 18, 2016 | none ahead |
| Pharmatech Oncologyits history only | 10 open or running | phase 2since Dec 7, 2001 | Dec 7, 2001 | none ahead |
| Relmada Therapeuticsits history only | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| RenovoRxits history only | 10 open or running | phase 1since Sep 8, 2014 | Sep 8, 2014 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| Smartwise Sweden ABits history only | 11 open or running | phase 2since Apr 5, 2026 | Apr 5, 2026 | Dec 2027phase 2 · NCT07575191 |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| SynerGene Therapeuticsits history only | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eisai only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2010First study: phase 2 study in Urinary Bladder NeoplasmsFirst studyNCT01126749 · 92 enrolled · United States, Germany, Netherlands and more
TargetBeta
“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Hydroxyurearule | Norgine | phase 4 | 15 |
Studies
The one study Eisai leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01126749Urinary Bladder Neoplasms · United States, Germany, Netherlands and more | 2 | Terminated | May 8, 2015 | 92 |
How it is read
Names in the registry
- “Gemcitabine”, 113 entries
- “gemcitabine”, 52 entries
- “gemcitabine hydrochloride”, 17 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “EndoTAG-1 and Gemcitabine”, 3 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 53 studies
- Carcinoma, Non-Small-Cell Lung, 42 studies
- Breast Neoplasms, 24 studies
- Neoplasms, 10 studies
- Biliary Tract Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.